PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Conjunctivitis - Market size and forecast 2018-2023 Keratitis - Market size and forecast 2018-2023 Blepharitis - Market size and forecast 2018-2023 Other eye infections - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Rising number of government initiatives Growing adoption of generics Saturation in the pipeline landscape PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Akorn Inc. Allergan Plc Bausch Health Companies Inc. Bayer AG Daiichi Sankyo Co. Ltd. GlaxoSmithKline Plc Novartis AG Pfizer Inc. Sanofi Santen Pharmaceutical Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Conjunctivitis - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Conjunctivitis - Year-over-year growth 2019-2023 (%) Exhibit 22: Keratitis - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Keratitis - Year-over-year growth 2019-2023 (%) Exhibit 24: Blepharitis - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Blepharitis - Year-over-year growth 2019-2023 (%) Exhibit 26: Other eye infections - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Other eye infections - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by type Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: Akorn Inc. - Vendor overview Exhibit 53: Akorn Inc. - Business segments Exhibit 54: Akorn Inc. - Organizational developments Exhibit 55: Akorn Inc. - Segment focus Exhibit 56: Akorn Inc. - Key offerings Exhibit 57: Akorn Inc. - Key customers Exhibit 58: Allergan Plc - Vendor overview Exhibit 59: Allergan Plc - Product segments Exhibit 60: Allergan Plc - Organizational developments Exhibit 61: Allergan Plc - Segment focus Exhibit 62: Allergan Plc - Key offerings Exhibit 63: Allergan Plc - Key customers Exhibit 64: Bausch Health Companies Inc. - Vendor overview Exhibit 65: Bausch Health Companies Inc. - Business segments Exhibit 66: Bausch Health Companies Inc. - Organizational developments Exhibit 67: Bausch Health Companies Inc. - Geographic focus Exhibit 68: Bausch Health Companies Inc. - Segment focus Exhibit 69: Bausch Health Companies Inc. - Key offerings Exhibit 70: Bausch Health Companies Inc. - Key customers Exhibit 71: Bayer AG - Vendor overview Exhibit 72: Bayer AG - Business segments Exhibit 73: Bayer AG - Organizational developments Exhibit 74: Bayer AG - Geographic focus Exhibit 75: Bayer AG - Segment focus Exhibit 76: Bayer AG - Key offerings Exhibit 77: Bayer AG - Key customers Exhibit 78: Daiichi Sankyo Co. Ltd. - Vendor overview Exhibit 79: Daiichi Sankyo Co. Ltd. - Business segments Exhibit 80: Daiichi Sankyo Co. Ltd. - Organizational developments Exhibit 81: Daiichi Sankyo Co. Ltd. - Geographic focus Exhibit 82: Daiichi Sankyo Co. Ltd. - Key offerings Exhibit 83: Daiichi Sankyo Co. Ltd. - Key customers Exhibit 84: GlaxoSmithKline Plc - Vendor overview Exhibit 85: GlaxoSmithKline Plc - Business segments Exhibit 86: GlaxoSmithKline Plc - Organizational developments Exhibit 87: GlaxoSmithKline Plc - Geographic focus Exhibit 88: GlaxoSmithKline Plc - Segment focus Exhibit 89: GlaxoSmithKline Plc - Key offerings Exhibit 90: GlaxoSmithKline Plc - Key customers Exhibit 91: Novartis AG - Vendor overview Exhibit 92: Novartis AG - Business segments Exhibit 93: Novartis AG - Organizational developments Exhibit 94: Novartis AG - Geographic focus Exhibit 95: Novartis AG - Segment focus Exhibit 96: Novartis AG - Key offerings Exhibit 97: Novartis AG - Key customers Exhibit 98: Pfizer Inc. - Vendor overview Exhibit 99: Pfizer Inc. - Business segments Exhibit 100: Pfizer Inc. - Organizational developments Exhibit 101: Pfizer Inc. - Geographic focus Exhibit 102: Pfizer Inc. - Segment focus Exhibit 103: Pfizer Inc. - Key offerings Exhibit 104: Pfizer Inc. - Key customers Exhibit 105: Sanofi - Vendor overview Exhibit 106: Sanofi - Business segment Exhibit 107: Sanofi - Organizational developments Exhibit 108: Sanofi - Geographic focus Exhibit 109: Sanofi - Segment focus Exhibit 110: Sanofi - Key offerings Exhibit 111: Sanofi - Key customers Exhibit 112: Santen Pharmaceutical Co. Ltd. - Vendor overview Exhibit 113: Santen Pharmaceutical Co. Ltd. - Business segments Exhibit 114: Santen Pharmaceutical Co. Ltd. - Organizational developments Exhibit 115: Santen Pharmaceutical Co. Ltd. - Geographic focus Exhibit 116: Santen Pharmaceutical Co. Ltd. - Segment focus Exhibit 117: Santen Pharmaceutical Co. Ltd. - Key offerings Exhibit 118: Santen Pharmaceutical Co. Ltd. - Key customers Exhibit 119: Validation techniques employed for market sizing Exhibit 120: Definition of market positioning of vendors

Akorn Inc. Allergan Plc Bausch Health Companies, Inc. Bayer AG Daiichi Sankyo Co. Ltd. GlaxoSmithKline Plc Novartis AG Pfizer Inc. Sanofi Santen Pharmaceutical Co. Ltd.